



## **SightGlass Vision Strengthens Leadership in Myopia Control with New Medical and Professional Affairs Appointments**

*David Webley and Fabio Carta bring new expertise to SightGlass Vision's  
medical and professional affairs teams*

**DALLAS, March 19, 2026**—SightGlass Vision is deepening its investment in medical and professional affairs with two recent leadership appointments. David Webley has joined as Senior Director, Clinical, Medical and Professional Affairs, and Fabio Carta joined in the newly created role of Director, Professional Affairs. Webley and Carta will expand SightGlass Vision's relationships with the global eye care community, providing increased support and education about DOT™ myopia control spectacle lenses.

DOT lenses correct vision and are designed to slow myopia progression through contrast management.<sup>[1],[2]</sup> Artificial contrast signals can overstimulate the retina leading to excessive axial length growth; DOT lenses mimic more natural contrast by integrating thousands of elements that softly scatter light before it hits the retina.<sup>[3],[4]</sup> Research has demonstrated that DOT lenses slow myopia progression by up to 75% after 12 months of wear across diverse populations.\*<sup>4,2</sup>

“The efficacy and safety of DOT lenses have already been clearly demonstrated,” said Webley.<sup>11</sup> “Our mission now is to continue SightGlass Vision's momentum by raising awareness of contrast management, helping more eye care professionals to understand how and why DOT lenses work so successfully, and ultimately, ensuring more children are wearing solutions that slow down the progression of myopia.”

Webley earned his BSc in Optometry from Aston University and worked in primary care practice for over a decade before moving into education and development roles with Vision Express in the U.K. He then spent over seven years at CooperVision in senior European professional affairs and marketing roles. He has served as chair of the British Contact Lens Association (BCLA) council since 2023.

Carta holds multiple diplomas from The Institute for Research and Studies in Optics and Optometry (IRSOO) in Vinci and has practiced for over 25 years. He consulted for Johnson & Johnson Vision Care and Bausch + Lomb Italy, after which he served in professional affairs roles at CooperVision and Menicon Holdings B.V. Europe, where he became increasingly focused on myopia management.

“DOT lenses are easy for eye care professionals to prescribe and for children to wear,” said Carta.<sup>#S11[5].[6]</sup> “That ease and efficacy make DOT lenses a key option for practices expanding into myopia management and for preserving more children’s eye health.”

SightGlass Vision’s DOT lenses have made their commercial debut in China, Canada, Israel, Spain, and the U.K., with over 1.5 million children having already worn the lenses.<sup>#L7]</sup> Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International.

For more information, visit [SightGlassVision.com](https://SightGlassVision.com).

###

### **About SightGlass Vision**

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

\* Patient population aged 6–10 years (CYPRESS) and 6–13 years (CATHAY). Prescribed DOT lens wear time was minimum 10 hours per day.

† <<DOT™ 0.2>> lenses have been demonstrated to be safe and effective at reducing myopia progression in children in a multi-center randomised controlled clinical trial conducted in the US and Canada.

‡ <<DOT™ 0.2>> lenses are easy to fit, without extra chair time as they are prescribed like many other single-vision spectacle lenses.

§ Ocular center height measurements required. Criticality of PD/OC measurements.

|| Glasses with <<DOT™ 0.2>> lenses are as easy to adapt to as regular single vision lenses.

# *SightGlass Vision™ products are not available for sale in the United States.*

Diffusion Optics Technology and DOT are trade marks of SightGlass Vision, Inc.© 2026 SightGlass Vision, Inc. All Rights Reserved.

### **Media Contact**

Carson Daniels, Senior Counselor

McDougall Communications for SightGlass Vision

+1-315-427-6394 or [carson@mcdougallpr.com](mailto:carson@mcdougallpr.com)

---

<sup>[1]</sup> Laughton D, et al. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS): BMJ Open Ophthalmology 2024;9:e001790;

<sup>[2]</sup> Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. Invest. Ophthalmol. Vis. Sci. 2025;66(8):2815.

<sup>[3]</sup> Neitz M et al. Insight from OPN1LW Gene Haplotypes into the Cause and Prevention of Myopia. Genes. 2022;13(6):942

<sup>[4]</sup> Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. Br J Ophthalmol 2023;107:1709-1715.1.

<sup>[5]</sup> Dispensing as single vision lens dispensing. Pupil centre height measurements required.

<sup>[6]</sup> McParland et al. Children adapt well to Diffusion Optics Technology™ (DOT™) spectacle lenses. Presented at NCC 2024

<sup>[7]</sup> SGV data on file 2025: 2024/25 sales data and repeat purchase rates; reflects global usage across multiple regions.